In 2024, biotechs were behind almost two-thirds of the FDA’s new drug approvals. Many biotechs are choosing to commercialize their products themselves, rather than partnering with Big Pharma players. Many fail, but some things have turned in biotech’s favor.

In this report, we look at the market dynamics that are enabling biotechs to go to market, and look at some of the companies aiming to do just that in the next few years. We also consider the best practices to make that dream a reality, consider key headwinds and tailwinds, and highlight the advantages that these small players sometimes have over the big guys.

We investigate:

• The steps involved in bringing a novel drug to market
• The successful biotechs leading the way in their fields
• The tailwinds driving biotechs onto the commercial battlefield

Read Now